Anergis (Switzerland) has gotten €4.5M from investors and is planning a phase IIb trial for ATIBAR, its leading candidate to treat Tree allergies. Anergis is developing ultra-fast immunotherapies for allergies, which could be an interesting alternative to current treatments, known as ‘desensitization’ or conventional Allergy Immunotherapy (AIT). This process of inducing tolerance to the allergen requires 3-5 […]